Question 1

What are the negative side effects of NAD+?

Accepted Answer

The honest answer starts with how little was written down, and then with where the little that exists came from. Among the research behind this page the recorded effects are rodent effects. In the anaesthesia experiment in mice, the NADH-treated group exhibited a significant decrease in open-field activity relative to vehicle-treated. That diminished activity was reflected in reduced distance travelled and average velocity after emergence from anesthesia in those mice. Less movement is the opposite of what the shelf copy promises. In people, the only trial on record was built to report results rather than harms. It ran for eight weeks in patients taking two compounds at once. So the side-effect column for a person is empty because nobody filled it in, which is a different thing from being empty because nothing happened.

Question 2

Is NAD+ hard on the liver?

Accepted Answer

Nobody looked, and saying that precisely is more use to a reader than guessing from mechanism. No study among the research behind this page reports a liver enzyme, a bilirubin figure or a scan in any person given NAD+ or one of its precursors. The mouse experiments counted behaviour, gut bacteria and immune signals. The one human trial set out to measure age-predicted maximum heart rate (max HR) during a cycle ergometer test, and secondary measures included fatigue, pain and sleep. Nothing else was published from it. A liver that was never tested is not a liver that passed. The mechanism argument runs the other way, since NAD+ is described as a core coenzyme involved in cellular energy metabolism and redox homeostasis. A mechanism is a reason to run the test rather than a substitute for running it.

Question 3

What is on record for a person, and over how long?

Accepted Answer

Eight weeks, eighty patients, two compounds at once. That is the whole human exposure among the research behind this page. The study was a proof-of-concept, 8-week, randomized, controlled, double-blind trial in people with chronic fatigue syndrome. Everyone in the active arm was assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice daily. Two readings moved and two did not. Perception of fatigue also showed a decrease through all follow-up visits in active group versus placebo. However, pain and sleep did not improve in the active group. A result produced by two compounds cannot be handed to one of them, and neither can a safety record. The authors wrote that further additional larger controlled trials are needed to confirm these findings, which is the right reading of eight weeks in eighty people.

Question 4

Does the anaesthesia result matter before surgery?

Accepted Answer

This is the one finding in this material with an obvious practical edge, and it came from mice rather than from a clinic. Intraperitoneal means an injection straight into the abdominal cavity, which is a laboratory route and not a clinical one. Adult male and female C57BL/6 mice (n = 8-10/group) were given NADH (150 mg/kg, intraperitoneal) or vehicle (0.9% normal saline) at baseline or during anesthesia. The conclusion is flat. This study demonstrates that NADH does not appear to hasten recovery from anesthesia, and the mice that got it moved less afterwards. The authors press the point, writing of the importance of understanding the potential influence of administering NAD+ on anesthetic sensitivity and recovery. A mouse at 150 mg per kilogram into the belly is a long way from a person swallowing a capsule before an operation, and that distance has not been measured.

Question 5

What is known about an NAD+ drip into a vein?

Accepted Answer

Almost nothing, and the gap is specific rather than vague. No study among the research behind this page gave NAD+ to a person by infusion. Nothing in that material describes what an hour on a drip delivers, how fast it is run, or what else shares the bag. The injections that do exist went into mice and into the abdominal cavity. In a mouse model of nerve-coating injury, animals received 250 mg/kg/day NAD+ intraperitoneally once a day, while the other mice were administered saline simultaneously. A clinic drip is a different concentration, a different route and a different rate from any of that. What is missing is not only an adverse-event list but the basic description of the exposure, which means nobody can say afterwards what was actually given.

Question 6

Can one molecule's record speak for another?

Accepted Answer

Four different molecules appear in these experiments, and a harm recorded for one of them is not a harm recorded for the rest. The anaesthesia work used NADH, a common NAD+ precursor. The delirium work used nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide. The Alzheimer's work used the nicotinamide adenine dinucleotide (NAD+) precursor, nicotinamide riboside (NR). Only the mouse brain work gave NAD+ itself, and the one human trial gave NADH alongside coenzyme Q10. A precursor is raw material a body still has to convert, and conversion is exactly where an unwanted effect can appear or disappear. Nothing among the research behind this page set the four against each other in one experiment, so a quiet record for one of them cannot be lent to the other three.

Question 7

Are there documented interactions with medicines?

Accepted Answer

None are documented, and the one combination that was tested makes the point better than the gap does. The single human trial gave CoQ10 plus NADH supplementation to everyone in its active arm, so even the two compounds in the capsule cannot be told apart. Nothing among the research behind this page gave NAD+ or a precursor alongside a prescription medicine and then watched what happened. Two registered studies show how mixtures get tested in practice. One is filed as Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity. Another is filed as Health Benefits of Nutraceutical Supplementation in Older Adults. Both test blends. A blend that was never taken apart cannot report which part caused anything, and that is as true of a harm as it is of a benefit.

Question 8

Does NAD+ change mood or behaviour?

Accepted Answer

Two mouse experiments measured mood-like behaviour, and both came back flat. In the cuprizone model, NAD+ supplementation does not show significant effects on depressive and exploratory behavior of experimental mice, even though the same animals did better on a maze and on grip and rotarod tests. In the delirium model, a precursor did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice. A cytokine is an immune signalling molecule. A panel of them did move in that delirium work, with partial improvement on the levels of IL-12p40, RANTES, LIX, and IL-17 which were sex-dependent. Shifting the immune signals of a sick mouse without changing how it behaves is a result that cuts both ways: it shows the compound is doing something, and it says nothing about whether that something is wanted.

Question 9

Does NAD+ change gut bacteria?

Accepted Answer

One experiment says yes, in mice bred to carry the marks of Alzheimer's disease, and it reads better as a safety question than as a benefit. After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in those mice. The list of species that moved includes Bifidobacterium, Akkermansia, and Lactobacillus, which are among the bacteria people buy probiotics to encourage. The same paper notes that there were gender differences in gut microbiome between female and male AD mice. Read it as a demonstration that a precursor reaches the gut and changes what lives there. Those mice started from a disturbed state, so coming back toward normal was the only direction available, and nothing among the research behind this page tested what eight weeks does to a gut that was never disturbed.

Question 10

What does the heart review actually report?

Accepted Answer

The largest NAD+ paper among the research behind this page is a review of mechanism, and reading it as a safety document would be a mistake. Its topic is heart failure, called there the terminal stage in the development of many cardiovascular diseases. Mitochondria are the parts of a cell that generate its energy, and the review's whole case runs through them. It states that NAD+ has been shown to potentially ameliorate heart failure through the regulation of mitochondrial function, and the authors describe their own paper as a theoretical basis for understanding the central role of NAD+ in mitochondrial homeostasis. A theoretical basis is a reason to start a trial, not a finding that came out of one. A review of mechanism contains no patients, so no cardiac harm could be recorded in it, and nothing in this material follows a person with a heart condition who is taking NAD+.

Question 11

Who was left out of the NAD+ research?

Accepted Answer

Almost everyone was left out, because the human record is a single population chosen for a condition rather than for a safety question. The eighty people in the trial had chronic fatigue syndrome, described in the same report as severe disabling fatigue with no known cause, no established diagnostic tests, and no universally effective treatment. Healthy adults were not enrolled. Neither were children, pregnant women, older adults as a group, nor anyone with kidney, liver or heart disease. That matters more than usual here, because fatigue is the symptom the whole consumer market is sold on. A result in people who are ill with a fatigue condition does not describe a healthy adult buying capsules for energy, and the second group has not been studied in this material at all.

Question 12

Is there a purity record for what people buy?

Accepted Answer

No source among the research behind this page measures the identity, purity or contamination of anything sold over a counter or given in a clinic. The nearest thing to an acknowledgement of that trade is a line in the anaesthesia paper, which observes that with rising over-the-counter use of NAD, understanding their impact on anesthetic recovery becomes essential. One registered study points at a named brand and is filed as Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels. It measures a level inside cells rather than the contents of a container. So a buyer has no published assay to hold a label against, and no way to tell from this material which of the four molecules a bottle holds. That is a hole in the record rather than a finding about any particular seller.

Question 13

Are any safety studies registered?

Accepted Answer

Seven studies naming NAD+ or one of its building blocks sit on the public register among the research behind this page, and none of them is a safety study. Two are marked COMPLETED and ask exercise questions: NR Supplementation and Exercise, and Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement. One is a PHASE2 study of skeletal muscle metabolism whose status reads UNKNOWN, which on that register usually means nobody came back to update it. One more, Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training, is marked RECRUITING. Every title names a performance outcome, a metabolic outcome or a blood level. A line on a public register is a plan somebody filed rather than an answer somebody found, and these plans are not aimed at the questions this page cannot settle.

Question 14

Why is the NAD+ harm record this thin?

Accepted Answer

There are three reasons, and none of them is reassuring. The first is that the literature is small and mostly theoretical. The 2025 heart paper calls itself a theoretical basis for understanding the central role of NAD+, and the Parkinson's paper is titled around A Potential Disease-Modifying Agent Targeting Multiple Pathways. Under those sit a handful of mouse experiments. The second is that those experiments were designed to test rescue in animals made ill on purpose, so harm in a healthy animal was never the endpoint. The delirium authors say as much, noting that whether Nicotinamide adenine dinucleotide supplementation may be beneficial for delirium has not been explored yet. The third is the shortest to state. Eight weeks of two compounds in eighty ill patients would not detect an uncommon event even if somebody had been looking for one.

NAD+ side effects and safety data